In colorectal cancer, it directly inhibits PD-L1 [96], in NSCLC it directly targets PD-L1 and PD-1 [97], and in glioblastoma it downregulates both PD-1 and CTLA4 expression [98], whose relevance in HCC is well-known. The gene discussed is CD274; the disease is glioblastoma.